Evidence map›Paper›PMID 30076531›Full record

ArticleMolecular biotechnology2018

Selection of Antibodies with Tailored Properties by Application of High-Throughput Multiparameter Fluorescence-Activated Cell Sorting of Yeast-Displayed Immune Libraries.

Christian Schröter, Jan Beck, Simon Krah, Stefan Zielonka, Achim Doerner, Laura Rhiel, Ralf Günther, Lars Toleikis, Harald Kolmar, Björn Hock and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Christian SchröterAntibody Drug Conjugates and Targeted NBE Therapeutics, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Jan BeckInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany.
Simon KrahProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Stefan ZielonkaProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Achim DoernerProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Laura RhielAntibody Drug Conjugates and Targeted NBE Therapeutics, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Ralf GüntherProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Lars ToleikisProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Harald KolmarInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany.
Björn HockAntibody Drug Conjugates and Targeted NBE Therapeutics, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Stefan BeckerProtein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany. Stefan.c.Becker@merckgroup.com.
Merck (Germany) · DETarget (Germany) · DETechnical University of Darmstadt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we present a multiparameter screening procedure for the identification of target-specific antibodies with prescribed properties. Based on B cell receptor gene repertoires from transgenic rats, yeast surface display libraries were generated, and high-affinity human antibodies were readily isolated. We demonstrate that specific desirable features, i.e., species' cross-reactivity and a broad epitope coverage can be integrated into the screening procedure using high-throughput fluorescence-activated cell sorting. We show that the applied screening stringencies translate directly into binding properties of isolated human antibody variants.

Indexed as

AnimalsAntibodies, MonoclonalAntibody AffinityCell LineCell SeparationCell Surface Display TechniquesCloning, MolecularFemaleFlow CytometryHumansMalePeptide LibraryRatsRats, TransgenicSaccharomyces cerevisiaeAntibodies, MonoclonalPeptide LibraryAffinityCombinatorial immune librariesFab displayFluorescence-activated cell sortingSpecificityYeast surface display

Identifiers

PMID30076531
PMCPMC6132741
OpenAlexW2885107034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.